natgillin/translations-raw huggingface dataset:
Forbigående normale symptomer efter vaccination kan også observeres, såsom: hyperthermi (der sædvanligvis varer 1 til 4 dage), apati, fordøjelsesforstyrrelser.
The transient common signs following vaccination may also be observed, such as: hyperthermia (lasting 1 to 4 days), apathy, digestive disturbances.
Forbigående normale symptomer efter vaccination kan også observeres, såsom: hyperthermi (der sædvanligvis varer 1 til 4 dage), apati, fordøjelsesforstyrrelser.
The transient common signs following vaccination may also be observed: hyperthermia (lasting1 to 4 days), apathy (listlessness), digestive disturbances (abdominal discomfort).
Forbigående oligospermi
Alopecia
forbigående opkastning
transitory vomiting
Forbigående rødme, kløe eller smerter på injektionsstedet
Temporary reddening, itchiness or pain at the injection site
Forbigående rødmen, kløe og andre symptomer på ubehag på applikationsstedet er sjældent rapporteret og forsvinder sædvanligvis spontant inden for et døgn efter administration af produktet.
Transient erythema, pruritus or other signs of discomfort at the application site have been reported rarely and usually disappear spontaneously, within 24 hours following administration of the product.
Forbigående rødmen, kløe og andre symptomer på ubehag på applikationsstedet er sjældent rapporteret og forsvinder sædvanligvis spontant inden for et døgn efter administration af præparatet.
Transient skin redness, itching or other signs of discomfort at the application site have been reported rarely and usually disappear without any treatment and within 24 hours after using the medicine.
forbigående stigning i serum IgM3
transient increase in serum IgM levels3
Forbigående stigninger i aspartat aminotransferase (AST), alanin aminotransferase (ALT), laktat dehydrogenase (LDH), bilirubin og leukocyttal kan forekomme ved sevofluran ligesom ved brug af andre halogenerede anæstesimidler.
Transient elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), bilirubin and white blood cell count may occur with sevoflurane, as with the use of other halogenated anaesthetic agents.
Forbigående stigninger i aspartat aminotransferase (AST), alanin aminotransferase (ALT), laktat dehydrogenase (LDH), bilirubin og leukocyttal kan forekomme ved sevofluran ligesom ved brug af andre halogenerede anæstesimidler.
Transient elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), bilirubin and white blood cell counts may occur with sevoflurane, as with the use of other halogenated anaesthetic agents.
Forbigående stigninger i IOP, inklusive forbigående blindhed og manglende perfusion af synsnerven, er konstateret inden for 60 minutter efter Jetrea- injektionen.
Transient increases in IOP including transient blindness and non-perfusion of the optic nerve have been seen within 60 minutes of injection of JETREA.
forbigående symptomer på slagtilfælde
temporary symptoms of a stroke
Forbigående symptomer som i en akut-fase respons (myalgi, utilpashed og sjældent feber), typisk i forbindelse med initiering af behandlingen†
transient symptoms as in an acute-phase response (myalgia, malaise and rarely, fever), typically in association with initiation of treatment
Forbigående symptomer som i et akut-fase respons (myalgi, utilpashed og sjældent feber), typisk i forbindelse med initiering af behandlingen†
transient symptoms as in an acute-phase response (myalgia, malaise and rarely, fever), typically in association with initiation of treatment
Forbigående trombocytopeni.
Transient thrombocytopenia.
Forbigående trombocytrespons defineres som ugentlige trombocyttal ≥ 50 x 109/l 4 gange eller mere i uge 2-25 af undersøgelsen, men uden en varig trombocytrespons.
Transient platelet response was defined as weekly platelet count ≥ 50 x 109/l for 4 or more times during study weeks 2-25 but without durable platelet response.
Forbigående udbredt oligospermi er rapporteret efter eksponering for 6–mercaptopurin i kombination med kortikosteroider.
Transient profound oligospermia has been reported following exposure to 6–mercaptopurine in combination with corticosteroids.
forbigående uklarhed i hornhinden gulfarvning af huden og det hvide i øjnene (gulsot).
cloudiness of the eye surface (transient corneal opacity) yellowing of the skin or whites of the eyes (jaundice).
Forbigående unormale resultater af leverfunktionstest, der tyder på nedsat leverfunktion med eller uden morfologiske ændringer i leverbiopsien, er også rapporteret i forbindelse med OHSS.
Transient liver function test abnormalities suggestive of hepatic dysfunction with or without morphologic changes on liver biopsy have also been reported in association with OHSS.
Forbigående øgning i serumkreatinin kan være højere hos patienter med underliggende nyresygdom.
Transient increase in serum creatinine may be greater in patients with underlying impaired renal function.
Forbigående øjenforandringer (se Klinisk erfaring)
Transient ocular changes (see Clinical experience).
Forbigående,
Transient,
Forbigående, asymptomatisk
Transient, asymptomatic
Forbigående, asymptomatisk
Transient, asymptomatic elevations of hepatic
Forbigående, asymptomatisk
Transient, asymptomatic elevations of hepatic aminotransferases
Forbigående, asymptomatisk forhøjede leveraminotransfer aser (ALAT, ASAT),
asymptomatic elevations of hepatic aminotransferases(A LT, AST), especially in
Forbigående, asymptomatisk forhøjede leveraminotransfer aser (ALAT, ASAT),
Transient, asymptomati c elevations of hepatic aminotransfe rases (ALT, AST),
Forbigående, asymptomatisk forhøjede leveraminotransfer aser (ALAT, ASAT),
Transient, asymptomatic elevations of hepatic aminotransferas es (ALT, AST),
Forbigående, asymptomatisk forhøjede leveraminotransfer aser (ALAT, ASAT), særlig initialt i
Transient, asymptomatic elevations of hepatic aminotransferas es (ALT, AST),
Forbigående, asymptomatisk forhøjede leveraminotransfer aser (ALAT, ASAT), særlig initialt i
Transient, asymptomatic elevations of hepatic aminotransferas es(ALT, AST),
Forbigående, asymptomatisk forhøjede leveraminotransfer aser (ALAT, ASAT), særlig initialt i
Transient, asymptomatic elevations of hepatic aminotransferase s (ALT, AST),
Forbigående, asymptomatisk forhøjede leveraminotransferaser (ALAT, ASAT), særlig
Transient, asymptomatic elevations of hepatic aminotransferases
Forbigående, asymptomatisk forhøjede leveraminotransferaser (ALAT, ASAT), særlig initialt i behandlingen (se pkt.
Transient, asymptomatic elevations of hepatic aminotransferases
Forbigående, asymptomatiske forhøjelser af leveraminotransferaser ALAT og ASAT er almindeligt forekommende, især initialt i behandlingen.
Transient, asymptomatic elevations of hepatic aminotransferases, ALT, AST have been seen commonly, especially in early treatment.
Forbigående, asymptomatiske forhøjelser af leveraminotransferaser, alaninaminotransferase (ALAT) og aspartataminotransferase (ASAT) er almindeligt forekommende, især i den tidlige behandling.
Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly,especially in early treatment.
Forbigående, asymptomatiske forhøjelser af leveraminotransferaser, alaninaminotransferase (ALAT), aspartataminotransferase (ASAT) er almindeligt forekommende, især initialt i behandlingen.
Transient, asymptomatic elevations of hepatic aminotransferases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment.
Forbigående, asymptomatiske forhøjelser af leveraminotransferaser, alanintransferase (ALAT) og aspartattransferase (ASAT) er almindeligt forekommende, især initialt i behandlingen.
Transient, asymptomatic elevations of hepatic aminotransferases , alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment.
Forbigående, asymptomatiske forhøjelser af leveraminotransferaser, alanintransferase (ALAT) og aspartattransferase (ASaT) er almindeligt forekommende, især initialt i behandlingen.
Transient, asymptomatic elevations of hepatic aminotransferases , alanine transferase (ALT), aspartatetransferase (AST) have been seen commonly, especially in early treatment.
Forbigående, asymptomatiske forhøjelser af leveraminotransferaser, alanintransferase (ALAT) og aspartattransferase (ASAT) er almindeligt forekommende, især initialt i behandlingen.
Transient, asymptomatic elevations of hepaticaminotransferases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment.
Forbigående, mindre stigninger i basisk fosfatase, LDH, ALAT (alaninaminotransferase) og urinsyre er rapporteret hos raske donorer, der fik filgrastim, men uden kliniske følger.
Transient, minor increases in alkaline phosphatase, LDH, SGOT (serum glutamic oxaloacetic transaminase) and uric acid have been reported in normal donors receiving filgrastim; these were without clinical sequelae.
Forbigående, moderat til markant temperaturforhøjelse samt lokalreaktioner (hævelse, rødme eller let smerte og i nogle tilfælde varme på injektionsstedet) kan forekomme efter administration af en overdosis (10 doser).
After the administration of an overdose (10 doses), transient moderate to marked hyperthermia, as well as local reactions (swelling, erythema or slight pain, and in some cases, heat at the injection site) may occur.
Forbind den korte slange på applikatoren til den ende af den lange luftslange med han-luer-lock.
Connect the short tube on the application device to the male luer-lock end of the long gas tube.
Forbind infusionssættet med NovoRapid PumpCart ved at påsætte adapteren på din pumpe.
Connect the infusion set with NovoRapid PumpCart by attaching the adapter onto your pump.
Forbind injektionssprøjten med hætteglassets tilpasningsstykke.
Connect the syringe to the vial adapter
Forbind patientens hånd med et blødt stort stykke gaze.
Wrap the patient’s treated hand with a soft, bulky, gauze dressing.
Forbindelse
Compound
forbindelse med buprenorphin.
associated with
forbindelse med den årlige revurdering
Annual reports within the annual re- assessment
forbindelse med et måltid (se pkt.
taken with a meal (see section 5.2).
Forbindelser, der undertrykker aktive oxygenspecies eller bortskaffer radikaler såsom dimethylsulfoxid, β-caroten, ætanol, formiat og mannitol ville forventes at mindske PDT- aktivitet.
Compounds that quench active oxygen species or scavenge radicals, such as dimethyl sulphoxide, b-carotene, ethanol, formate and mannitol would be expected to decrease PDT activity.
Forbindelser, der undertrykker aktive oxygenspecies eller bortskaffer radikaler såsom dimethylsulfoxid, β-caroten, ætanol, formiat og mannitol ville forventes at mindske PDT-aktivitet.
Compounds that quench active oxygen species or scavenge radicals, such as dimethyl sulphoxide, b- carotene, ethanol, formate and mannitol would be expected to decrease PDT activity.
Forbindelsesstykke til hætteglas
Vial adapter
Forbindelsesstykke til hætteglas:
Vial adapter:
Forbindelsesstykket vil fæstne sig til hætteglassets hætte.
The adapter will snap over the vial cap.
forbindes med rifabutin-
adverse events associated with
Forblev på baseline- program-arm (SBR) n = 159
Stayed on Baseline Regimen (SBR) arm n = 159
Forbliver >33% over gennemsnittet fra før behandling
Remains >33% above pre-treatment average
Forbliver effektivt selvom dyret bliver udsat for sollys eller bliver vådt af regn, badning eller anden kontakt med vand.
Remains effective after exposure to sunlight or if the animal becomes wet after rain, bathing, or water immersion.
Forbrænding, solskoldning2
Thermal burn, sunburn2
forbrændinger i det perianale og genitale område. elektriske forbrændinger.
perineal and genital burns. electrical burns.
FORBUD MOD SALG, LEVERING OG/ELLER BRUG
PROHIBITION OF SALE, SUPPLY AND/OR USE
FORBUD MOD SALG, UDLEVERING OG/ELLER BRUG
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE
FORBUD MOD SALG, UDLEVERING OG/ELLER BRUG
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT
FORBUD MOD SALG, UDLEVERING OG/ELLER BRUG
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
FORBUD MOD SALG, UDLEVERING/BRUG
PROHIBITION OF SALE, SUPPLY AND/OR USE
FORBUD MOR SALG, UDLEVERING OG/ELLER BRUG
PROHIBITION OF SALE, SUPPLY AND/OR USE
forbundet med dannelsen af blodpropper overdreven spilletrang eller tidligere har gjort det
formation of blood clots past experience of excessive gambling
FORCALTONIN 100 I.E opløsning til injektion, rekombinant laksecalcitonin
FORCALTONIN 100 IU Solution for Injection, recombinant salmon calcitonin
Forcaltonin 100 IU opløsning til injektion.
Forcaltonin 100 IU solution for injection
FORCALTONIN 100 IU opløsningsvæske til injektion
FORCALTONIN 100 IU solution for injection
FORCALTONIN 100 IU opløsningsvæske til injektion Rekombinant laksecalcitonin
FORCALTONIN 100 IU solution for injection Recombinant salmon calcitonin
Forcaltonin gives ved subkutan indsprøjtning (under huden), intramuskulær indsprøjtning (i en muskel) eller intravenøs infusion (dryptilførsel i en vene – kun ved hyperkalcæmi).
Forcaltonin is given by subcutaneous injection (under the skin), intramuscular injection (into a muscle) or intravenous infusion (drip into a vein – only in hypercalcaemia).
FORCALTONIN og børn:
Use of FORCALTONIN in children:
Forced vital capacity (procentdel af forventet normalværdi)
Forced Vital Capacity (Percent of predicted normal)
Forceret diurese og alkalinisering af urinen, hvis der opstår muskelskade med øgede myoglobin niveauer i plasma og urin.
Forced diuresis and alkalinisation of the urine, if a muscle damage occurs with increased myoglobin levels in plasma and urine.
Fordel den tilladte mængde fedt jævnt mellem dagens måltider.
Distribute your fat allowance evenly across your meals for the day.
Fordele og mulige risici ved crizotinib skal overvejes før behandlingen indledes hos patienter med præeksisterende bradykardi, som tidligere har haft eller er disponeret for QTc- forlængelse, som tager antiarytmika eller andre lægemidler, der kan forlænge QT-intervallet, og hos patienter med relevant præeksisterende hjertesygdom og/eller elektrolytforstyrrelser.
The benefits and potential risks of crizotinib should be considered before beginning therapy in patients with pre-existing bradycardia, who have a history of or predisposition for QTc prolongation, who are taking antiarrhythmics or other medicinal products that are known to prolong QT interval and in patients with relevant pre-existing cardiac disease and/or electrolyte disturbances.
Fordele og ricisi skal evalueres, inden behandling med dabrafenib fortsættes hos patienter med en ikke-kutan malignitet, som har en RAS-mutation.
The benefits and risks should be considered before continuing treatment with dabrafenib in patients with a non-cutaneous malignancy that has a RAS mutation.
Fordele og risici ved > 2 behandlingsforløb er endnu ikke fuldt klarlagt, men resultaterne tyder på, at sikkerhedsprofilen ikke synes at ændre sig med yderligere behandlinger.
The benefits and risks of >2 treatment courses have not been fully established, but results suggest that the safety profile does not appear to change with additional courses.
Fordele og ulemper ved behandling af patienter med fastslået hyperlipidæmi bør overvejes, før immunsupprimerende behand- ling herunder Rapamune påbegyndes.
The risk/benefit should be considered in patients with established hyperlipidaemia before initiating an immunosuppressive regimen, including Rapamune.
Fordele og ulemper ved behandling med TYSABRI under graviditet skal afvejes i forhold til patientens kliniske tilstand og risikoen for fornyet sygdomsaktivitet ved behandlingsstop med lægemidlet.
A benefit-risk evaluation of the use of TYSABRI during pregnancy should take into account the patient’s clinical condition and the possible return of disease activity after stopping the medicinal product.
Fordele ved Strensiq påvist i kliniske studier
What benefits of Strensiq have been shown in clinical studies
Fordelen for barnet ved amning og fordelen for kvinden ved behandling skal tages i betragtning.
The benefit of breast-feeding for the child and the benefit of therapy for the woman should be taken into account.
Fordelen med hensyn til PFS blev konsistent observeret i de fleste patientgrupper, som blev analyseret i forhold til sygdomsrisikoen ved baseline (dvs.
The benefit in terms of PFS was consistently observed in most patient subgroups analysed according to disease risk at baseline (i.e.
Fordelen med hensyn til PFS blev konsistent observeret i de fleste patientundergrupper, som blev analyseret i forhold til sygdomsrisikoen ved baseline (dvs.
The benefit in terms of PFS was consistently observed in most patient subgroups analysed according to disease risk at baseline (i.e.
Fordelen var mindre, når Cyramza blev givet alene, men det kan stadig være en behandlingsmulighed, når behandling med paclitaxel ikke anses for at være hensigtsmæssig.
The benefit was smaller when Cyramza was given on its own, but this could still be a therapeutic option when treatment with paclitaxel is not considered appropriate.
Fordelen ved Agenerase oral opløsning boostet med ritonavir er ikke påvist hos PI-naive patienter og hos patienter, der tidligere er behandlet med PI’er.
The benefit of Agenerase oral solution boosted with ritonavir has not been demonstrated either in PI naïve patients or in PI experienced patients.
Fordelen ved aprepitant-kombinationsterapi i den totale undersøgelsespopulation var hovedsageligt drevet af de resultater, der sås hos patienter, der blev dårligt kontrolleret med standardregimet, som for eksempel hos kvinder, selvom resultaterne numerisk var bedre, når man så bort fra alder, tumortype eller køn.
The benefit of aprepitant combination therapy in the full study population was mainly driven by the results observed in patients with poor control with the standard regimen such as in women, even though the results were numerically better regardless of age, tumour type or gender.
Fordelen ved at bruge Cosentyx til aktiv gigt i rygsøjlen er, at det mindsker tegn og symptomer på din sygdom og forbedrer din fysiske funktion.
Using Cosentyx in ankylosing spondylitis will benefit you by reducing the signs and symptoms of your disease and improving your physical function.
Fordelen ved KRd for så vidt angår PFS blev observeret konsekvent i alle delgrupper, herunder patienter ≥ 75 år (n = 96), patienter med høj risiko (n = 100) eller ukendt risiko (n = 375) for genetiske mutationer samt patienter med en kreatininclearance ved baseline på 30 - < 50 ml/min (n = 56).
The PFS benefit of KRd was consistently observed in all subgroups, including patients ≥ 75 years of age (n = 96), patients with high risk (n = 100) or unknown (n = 375) risk genetic mutations, and patients with baseline creatinine clearance of 30 - < 50mL/min (n = 56).
Fordelen ved MabThera vedligeholdelsesbehandling blev bekræftet af alle undergruppeanalyser, uafhængigt af induktionsbehandlingen (CHOP eller R-CHOP) eller graden af respons på induktionsbehandlingen (CR eller PR) (tabel 7).
The benefit of MabThera maintenance treatment was confirmed in all subgroups analysed, regardless of induction regimen (CHOP or R-CHOP) or quality of response to induction treatment (CR or PR) (table 7).
Fordelen ved samtidig administration af amprenavir og ritonavir er ikke påvist hos patienter, som ikke tidligere er behandlet med proteasehæmmere.
The benefit of amprenavir boosted with ritonavir has not been demonstrated in PI naïve patients.
Fordelene af Nucala ved svær eosinofil astma, der ikke har været velkontrolleret med den foregående behandling, er påvist i tre hovedundersøgelser, hvor det blev sammenlignet med virkningsløs behandling (placebo).
The benefits of Nucala in severe eosinophilic asthma that is not well controlled by previous treatment have been shown in three main studies, in which it was compared with a placebo (dummy) injection.
Fordelene for det ammede spædbarn ved overført immunitet via brystmælk kan dog opveje risiciene ved potentiel udsættelse for alemtuzumab.
However, benefits of conferred immunity through breast-milk may outweigh the risks of potential exposure to alemtuzumab for the breastfed child.
Fordelene og risiciene ved at vaccinere patienten i løbet af Provenge-behandlingsforløbet er ikke blevet undersøgt.
The risks and benefits of vaccinating patients during the course of treatment with Provenge have not been studied.
Fordelene og risiciene ved Budesonide/Formoterol Teva Pharma B.V. antages derfor at være de samme som med referencelægemidlet
The benefits and risks of Budesonide/Formoterol Teva Pharma B.V. are therefore taken to be the same as those of the reference medicine.
Fordelene ved behandling med enoxaparin, der var indlysende for at antal forskellige effektresultater, viste sig efter 48 timer, hvor der var en reduktion på 35 % i den relative risiko for reinfarkt sammenlignet med ufraktioneret heparin (p < 0,0001).
The treatment benefits of enoxaparin, evident for a number of efficacy outcomes, emerged at 48 hours, at which time there was a 35% reduction in the relative risk of myocardial re-infarction, as compared with unfractionated heparin (p < 0.0001).
Fordelene ved behandling med enoxaparin, der var indlysende for et antal forskellige effektresultater, viste sig efter 48 timer, hvor der var en reduktion på 35 % i den relative risiko for reinfarkt sammenlignet med ufraktioneret heparin (p < 0,0001).
The treatment benefits of enoxaparin, evident for a number of efficacy outcomes, emerged at 48 hours, at which time there was a 35% reduction in the relative risk of myocardial re-infarction, as compared with unfractionated heparin (p < 0.0001).
Fordelene ved behandling med hensyn til opnåelse af opretholdt virologisk resons (SVR) sammenlignet med placebo var beskedne hos disse patienter (specielt for patienter med baseline albumin-niveau ≤ 35 g/l) sammenlignet med gruppen overordnet set.
In addition, the benefits of treatment in terms of the proportion achieving sustained virological response (SVR) compared with placebo were modest in these patients (especially for those with baseline albumin ≤ 35g/L) compared with the group overall.
Fordelene ved behandling med hensyn til opnåelse af SVR sammenlignet med placebo var beskedne hos disse patienter (specielt for patienter med baseline albumin-niveau ≤ 35 g/l) sammenlignet med gruppen overordnet set.
In addition, the benefits of treatment in terms of the proportion achieving SVR compared with placebo were modest in these patients (especially for those with baseline albumin ≤ 35 g/L) compared with the group overall.
Fordelene ved behandling med Uptravi ved pulmonal arteriel hypertension er påvist i en hovedundersøgelse med 1 165 patienter med pulmonal arteriel hypertension.
The benefits of Uptravi for PAH were shown in one main study involving 1,156 patients with PAH.
Fordelene ved Caprelsa kan være mindre for de patienter, der ikke har en mutation i et gen, der kaldes RET-genet (Rearranged during transfection), eller hvis dette ikke kendes, og det bør tages med i overvejelserne om eventuel behandlingsstart.
The benefits of Caprelsa may be smaller for patients who do not have a mutation in a gene called the ‘rearranged during transfection’ (RET) gene or if this is not known, and this should be taken into account when deciding whether to start treatment.
Fordelene ved EndolucinBeta afhænger hovedsagelig af det lægemiddel, som det anvendes til radioaktiv mærkning af.
The benefits of EndolucinBeta will largely depend on the medicine that it is used to radiolabel.
Fordelene ved Eperzan blev undersøgt hos over 5 000 patienter med type 2 sukkersyge, hos hvem Eperzan blev sammenlignet med placebo (virkningsløs behandling) eller med andre lægemidler mod sukkersyge, hvor det blev anvendt som tillægsbehandling til forskellige kombinationsbehandlinger eller blev anvendt alene.
The benefits of Eperzan were studied in over 5,000 patients with type 2 diabetes in which Eperzan was compared with placebo (a dummy treatment) or with other diabetes medicines when used as an add- on to various combination treatments or when used alone.